Clinical trial
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With…
NCT03248492 · Daiichi Sankyo, Industry · Terminated
Key facts
| NCT number | NCT03248492 |
|---|---|
| Title | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) |
| Official title | A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01) |
| Lead sponsor | Daiichi Sankyo, Industry |
| Collaborators | AstraZeneca Industry Daiichi Sankyo Co., Ltd. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | DS-8201a |
| Enrollment | 253 |
| Start date | Aug 25, 2017 |
| Primary completion | Mar 21, 2019 |
| Completion | May 6, 2024 |
| First posted | Aug 14, 2017 |
| Last update posted | Jun 26, 2025 |
| Countries | Belgium, Canada, France, Italy, Japan, South Korea, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: